Complete Guide to Imfinzi (Durvalumab) Pharmacokinetics
Overview
Imfinzi (Durvalumab) is a mAb used in the Oncology therapeutic area. It is indicated for Non-small cell lung cancer. Simulate Imfinzi (durvalumab) pharmacokinetics. This PK simulator models the anti-PD-L1 immune checkpoint inhibitor used for unresectable stage III NSCLC.
Mechanism of Action
Imfinzi (Durvalumab) exerts its pharmacological effect by targeting PD-L1. As a mAb, it modulates this target to achieve therapeutic efficacy in Non-small cell lung cancer. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This 2-CMT PopPK model for Imfinzi (Durvalumab) characterizes the time-course of drug concentrations following IV administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Imfinzi (Durvalumab) is administered via the IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Non-small cell lung cancer, understanding the pharmacokinetics of Imfinzi (Durvalumab) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Imfinzi (Durvalumab) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Imfinzi (Durvalumab) PK Simulator
Explore Imfinzi (Durvalumab) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Imfinzi (Durvalumab)?
The elimination half-life of Imfinzi (Durvalumab) depends on patient-specific factors. Use our interactive Imfinzi (Durvalumab) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Imfinzi (Durvalumab) administered?
Imfinzi (Durvalumab) is administered via the IV route. It is indicated for Non-small cell lung cancer. As a mAb, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Imfinzi (Durvalumab)?
Key pharmacokinetic parameters for Imfinzi (Durvalumab) include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a 2-CMT PopPK model to characterize the pharmacokinetics of Imfinzi (Durvalumab).
Can I simulate Imfinzi (Durvalumab) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Imfinzi (Durvalumab) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.